PMID- 34603014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211005
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Folate Reverses NF-kappaB p65/Rela/IL-6 Level Induced by Hyperhomocysteinemia in 
      Spontaneously Hypertensive Rats.
PG  - 651582
LID - 10.3389/fphar.2021.651582 [doi]
LID - 651582
AB  - Hyperhomocysteinemia (HHcy) is derived from the abnormal metabolism of 
      homocysteine (Hcy) and is related to metabolic-related diseases. In addition, 
      HHcy combined with hypertension increases the risk of cardiovascular diseases 
      (CVD). However, the mechanism of HHcy aggravating hypertensive arterial damage 
      and the efficacy of folate (FA) as a beneficial supplement have not been fully 
      elucidated. In this study, we established a rat HHcy model and a hypertension 
      combined with HHcy model. Rat tail artery blood pressure (BP), plasma Hcy, serum 
      superoxide dismutase (SOD), and malondialdehyde (MDA) were measured. Rat thoracic 
      aorta was for pathological analysis after 12 weeks of the experiment. The 
      relative expression levels of oxidative stress and immune/inflammation in rat 
      arterial tissues were detected by quantitative real-time polymerase chain 
      reaction (qRT-PCR) and western blotting. The results demonstrated that the 
      relative expression levels of oxidative stress and immune/inflammation were the 
      highest in the hypertension combined with HHcy group, followed by the 
      hypertension group. Compared with the hypertension group, the hypertension 
      combined with HHcy group up-regulated the expression levels of interleukin-6 
      (IL-6) and nuclear factor-kappa-gene binding (NF-kappaB) p65/Rela, but not NADPH oxidase 
      (Nox). Furthermore, folate inhibited the expression of IL-6 and NF-kappaB p65/Rela, 
      reduced the levels of MDA and HHcy, but significantly increased the SOD level. In 
      conclusion, HHcy synergistically aggravated the arterial damage factor of 
      hypertension through immune/inflammatory response. However, folate demonstrated 
      anti-inflammatory properties and reversed the NF-kappaB p65/Rela/IL-6 level induced 
      by HHcy in hypertensive rats.
CI  - Copyright (c) 2021 Zhang, Li, Xing, Gao and Xu.
FAU - Zhang, Lihua
AU  - Zhang L
AD  - Cheeloo College of Medicine, Shandong Qianfoshan Hospital, Shandong University, 
      Jinan, China.
AD  - Department of Medicine, Jinan Maternity and Child Care Hospital Affiliated to 
      Shandong First Medical University, Jinan, China.
FAU - Li, Zhongliang
AU  - Li Z
AD  - Department of Women Healthcare, Jinan Maternity and Child Care Hospital 
      Affiliated to Shandong First Medical University, Jinan, China.
FAU - Xing, Changcheng
AU  - Xing C
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan, China.
FAU - Gao, Ning
AU  - Gao N
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan, China.
FAU - Xu, Rui
AU  - Xu R
AD  - Cheeloo College of Medicine, Shandong Qianfoshan Hospital, Shandong University, 
      Jinan, China.
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University, Jinan, China.
LA  - eng
PT  - Journal Article
DEP - 20210916
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8481771
OTO - NOTNLM
OT  - arterial inflammation
OT  - folate
OT  - hyperhomocysteinemia
OT  - hypertension
OT  - oxidative stress
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/05 06:00
MHDA- 2021/10/05 06:01
PMCR- 2021/09/16
CRDT- 2021/10/04 05:56
PHST- 2021/01/10 00:00 [received]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/10/04 05:56 [entrez]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2021/10/05 06:01 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - 651582 [pii]
AID - 10.3389/fphar.2021.651582 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Sep 16;12:651582. doi: 10.3389/fphar.2021.651582. 
      eCollection 2021.